

AEterna Zentaris Inc.

10:55 07 Nov 2018

Aeterna Zentaris sees revenue boost in 3Q, ends the quarter debt-free

Aeterna Zentaris Inc (NASDAQ:AEZS) reported a narrower loss in this year's third-quarter results, more than doubling its revenue.

The biotech reported a net loss of \$0.15 per share on revenue of \$663,000 compared with a net loss of \$0.61 on revenue of \$241,000 in the previous year's third quarter.

The South Carolina-based company ended the quarter debt-free with \$16.8 million in cash on hand.

Shares slipped nearly 7% to \$2.21 in Wednesday morning trading.

READ: Nemauro develops predictive algorithms, alarm functionality for its sugarBEAT glucose monitor

Aeterna Zentaris entered into a licensing agreement with a subsidiary of Strongbridge Ireland Ltd back in January 2018 to develop Macrilen, also known as macimorelin, in the US and Canada.

Macrilen is used in the diagnosis of adult growth hormone deficiency, a rare endocrine disorder.

In early November, Strongbridge BioPharma signed an agreement with Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) to hand over the rights to Macrilen in the US and Canada.

The company has been advancing its plans to move into Europe, submitting Macrilen to the European Medicines Agency's Committee for Medicinal Products for Human Use.

The CHMP takes part in authorizing the use of medicines in the European Union.

"We are very pleased with the progress we are making in the European Union and of the Company's Day-181 CHMP submission of macimorelin to the European Medicines Agency last month and anticipate a decision from the European Commission in the first quarter of 2019," said CEO Michael V. Ward in the company's press release.

The drug development company specializes in oncology and endocrine therapy.

Contact Lenore Fedow at lenore@proactiveinvestors.com

Follow her on Twitter: [@LenoreMariee](https://twitter.com/LenoreMariee)

Price: 1

Market Cap: \$23.47 m

1 Year Share Price Graph



April 2019 October 2019 April 2020

Share Information

Code: AEZS

Listing: TSX

52 week	High	Low
	7.37	0.59

Sector: Pharma & Biotech

Website: www.aezsinc.com

Company Synopsis:

AEterna Zentaris Inc. is a drug development company specialized in oncology and endocrine therapy. The Company's product pipeline encompasses compounds at all stages of development, from drug discovery through marketed products.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.